European Union: Supplementary Protection Certificates: The CJEU Issues Its Decision In Two Seminal Cases

Last Updated: 16 April 2012
Article by John Miles, Michael Pears and Mike Snodin

On 24 November 2011, the Court of Justice of the European Union (CJEU) delivered its judgement in two seminal cases relating to Supplementary Protection Certificates (SPCs). Potter Clarkson represented Georgetown University, University of Rochester and Loyola University of Chicago in one case and the party in the other case was Medeva. Our IP Update No 155 discusses the corresponding Advocate General's opinion, which opinion is superseded by the present judgement. The ruling provides significant clarity and is binding on all EU national patent offices and courts.

SPCs and their availability

SPCs provide additional protection, beyond patent expiry, for products (medicinal or plant protection) that require a marketing authorisation.

Under Regulation (EC) No 469/2009, any "product" that is protected by a basic patent in force and that is validly authorised to be placed on the market as a medicinal product, is eligible for SPC protection, provided that it is new to the market and has not previously been protected by an SPC. The term "product" is defined as: "the active ingredient or combination of active ingredients of a medicinal product".

Cases concerning authorised medicinal products that contain a combination of active ingredients (e.g. A+B) have now brought two issues into sharp relief:

  1. What are the criteria for determining whether a Product is 'protected' by a basic patent in force?
  2. What is a 'valid authorisation' to place the Product on the market as a medicinal product?

Medeva and Georgetown University et al references

These issues have now been considered by the CJEU upon referral from the UK Courts in appeals lodged by Medeva and Georgetown University et al (cases C-322/10 and C-422/10, respectively).

Both Medeva's and Georgetown University et al's SPC applications relate to vaccines containing multiple antigens authorised in combination. The allowability of the Georgetown University et al and one of the Medeva applications hinges on whether a marketing authorisation for a combination vaccine is a 'valid authorisation' for Products defined as just one of the antigens, or a sub-combination of antigens, present in the vaccine. The allowability of Medeva's other applications depends upon whether a patent that discloses some, but not all, of the antigens in an approved vaccine nevertheless 'protects' the entire combination of antigens for the purpose of securing an SPC.

CJEU's judgment

The CJEU has decided the following.

  1. For an SPC to be granted, the active ingredients representing the Product must be specified in the wording of the claims of the basic patent.
  2. The Product can be defined as a single active ingredient (or as a sub-combination of active ingredients) even when the medicinal product includes further active ingredients.
  3. An SPC provides the same protection as the basic patent against an unauthorised use of the Product in the form of any medicinal product that contains that Product (meaning that an SPC to Product A would be infringed, for example, by sale of a medicinal product containing active ingredients A + B).
  4. Where a basic patent protects a Product, only one certificate may be granted for that basic patent.


The rulings provide clarity on many points, but arguably leave open room for interpretation on others.

What is now absolutely clear are points (b) and (c) above. Further, point (a) above also clarifies that, for SPCs, it is not appropriate to assess the "protection" afforded by a basic patent by using the kind of infringement test that would usually be employed in patent enforcement / validity proceedings.

In connection with point (a), however, there remains some uncertainty. That is, although some degree of 'specification' of each active ingredient is clearly required, it is not yet known how general the definition of each active ingredient may be whilst still satisfying the requirement of being "specified in the wording of the claims". The test may be broad, requiring merely a positive recitation of claim features that read on each active ingredient. On the other hand, it may be a narrow test, requiring unambiguous individualisation of each active ingredient, or it may instead be something in between.

Finally, there is room for argument that point (d) above means that, for any given basic patent, only one SPC may be available per Product. However, it remains to be seen whether the national courts in Europe will accept this interpretation, or will instead insist on a much more restrictive one SPC per patent rule (regardless of how many different active agents are "protected" by a basic patent). The practice of national patent offices to date has been to accept the former, more generous interpretation, in spite of an earlier case (Biogen, C-181/95) that contained a statement much along the lines of point (d) above.

Action points

Aside from the areas of uncertainty that remain, the rulings offer a clear package of rights in the circumstances where a basic patent protects one or more active ingredients which are authorised for the first time in the EU together with one or more other active ingredients. This holistic approach was the one proposed by us on behalf of Georgetown University et al, and provides opportunity for obtaining useful and very broad SPC protection.

Moreover, the rulings will have immediate and far-reaching consequences not only in relation to the broad SPC protection that might now be granted by patent offices in Europe, but also in connection with the scope and validity of SPCs already granted.

Please therefore contact us if you have any queries regarding the scope and/or validity of SPC protection that you may wish to seek, or that is associated with the granted SPCs of others.

If you require any further information, please contact John Miles, Mike Snodin or Michael Pears of our SPC & Regulatory group. John and Michael acted for Georgetown University et al in this matter.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.